Last Update: Jul 15, 2026 Real-World Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab in Italy ClinicalTrials.gov Identifier: [NCT07543731](https://clinicaltrials.gov/ct2/show/NCT07543731) Novartis Reference Number:CKJX839A12404 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice. Condition Cardiovascular Diseases, Atherosclerotic Cardiovascular Disease, Hypercholesterolemia, Familial Overall Status Recruiting Number of Participants5995 Start Date Apr 02, 2026 Completion Date Oct 30, 2026 Gender All Age(s) 18 Years - 99 Years (Adult, Older Adult) ## Eligibility Criteria Inclusion criteria: \* A first ever prescription of injection of inclisiran, evolocumab, or alirocumab during the identification period. \* Age ≥18 years at index date. \* With at least 12 months data availability prior to index date. Exclusion criteria: • Patients who received either evolocumab or alirocumab as their index study drug and who were dispensed the other anti-PCSK9-mAb (alirocumab and evolocumab respectively) before the identification period. Switzerland #### Novartis Recruiting Basel,Ch-4056,Switzerland ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: